Tuesday, May 1, 2012
Hemispherx Biopharma Inc., of Philadelphia, said Ampligen (rintatolimod), an experimental immunotherapeutic, was administered intranasally in conjunction with FluMist (influenza vaccine live, intranasal) to healthy volunteers in a study at the University of Alabama at Birmingham.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.